Medindia

X

Sinobiomed Directors Confirm Hiring of New Chief Financial Officer

Thursday, October 9, 2008 General News J E 4
Advertisement
SHANGHAI, China, Oct. 8 Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTC Bulletin Board: SOBM) is pleased to announce that its Board of Directors voted on October 2, 2008 to officially appoint Lionel Choong as the Company's Chief Financial Officer under a Corporate Consulting Services Agreement to be effective as of September 1, 2008. In addition, Mr. Choong has been appointed to the Company's audit committee. An earlier news release dated August 13, 2008 that first announced the hiring can be viewed on the Company website. (www.sinobiomed.com).



As CFO, Mr. Choong will oversee the Company's various financial functions, including finance and accounting, financial planning and analysis, regulatory and risk management, and facilities development. He will also be involved with other corporate activities working with the Company's CEO, Banyun Yang, to develop strategies and tactics for long-term growth.



ABOUT SINOBIOMED INC.

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.



SINOBIOMED INC.

LANE 4705, NO. 58, NORTH YANG GAO RD.

PUDONG, NEW AREA SHANGHAI, 201206 CHINA

PHONE: 86-58993708 / FAX: 86-58993709

INVESTOR RELATIONS

PHONE: 1-718-502-8801 TOLL FREE: 1-866-588-0829

EMAIL: INFO@SINOBIOMED.COM



FORWARD LOOKING STATEMENTS This news release may include "forward-looking

statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.







SOURCE Sinobiomed Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Touchstone Health Partners with the American Heart...
S
Plexus Online Enhances Functions for Medical Devic...